The association of efficacy of TACE and prognosis with MDR1 gene expression in patients with hepatic cancer
10.3781/j.issn.1000-7431.2015.44.005
- Author:
Zhao-Yu WU
1
Author Information
1. Department of Interventional Radiology, Affiliated Hospital, Qinghai University
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Multidrug resistance;
Prognosis;
Transcatheter arterial chemoembolization
- From:
Tumor
2015;35(3):340-345
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To Investigate the effects of multidrug resistance gene 1(MDR1) expression on efficacy of transcatheter arterial chemoembolization (TACE) and prognosis in patients with hepatic cancer. Methods: Ninety patients with primary hepatocellular carcinoma were treated with TACE. The expression of MDR1 mRNA was measured by RT-PCR. The positive expression rates of MDR1 in hepatic cancer patients with different histologic types and differentiation degrees before and after TACE were compared. The total response rates, median survival time, 1-year survival rate and 2-year survival rate of MDR1-positive and MDR1-negative patients with hepatic cancer were analyzed. The levels of aspartate transaminase, alanine transarninase, albumin, alkline phosphatase, gamma-glutamyl transpeptidase, white blood cell, red blood corpuscle, hemoglobin and platelet in peripheral blood of patients with hepatic cancer before and after TACE were compared. Results: The positive expression rates of MDR1 in pseudoglandular tissues and hepatic tissues with II, III and IV differentiation degrees increased significantly after TACE therapy, as compared with those before TACE therapy (P < 0.01, P < 0.01, P < 0.05, P < 0.05). The total response rate, median survival time, 1-year survival rate and 2-year survival rate of MDR1 - negative patients were higher than those of MDR1-positive patients (P < 0.01, P < 0.01, P < 0.05, P < 0.05). One month after TACE therapy, only red blood corpuscle and hemoglobin levels did not return to normal levels. Conclusion: The expression of MDR1 in hepatocellular cancer tissues may be related to the efficacy of TACE.
